Determination of α-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571

Blood Cells, Molecules, and Diseases

Volumn 28, Issue 1, 2002, Pages 75-85

  Le Coutre, Philipp ^a   Kreuzer, Karl Anton ^a   Na, Il Kang ^a   Lupberger, Joachim ^a   Holdhoff, Matthias ^a   Appelt, Christine ^a   Schwarz, Michaela ^a   Müller, Christian ^a   Gambacorti Passerini, Carlo ^b   Platzbecker, Uwe ^c   Bonnet, Ragnhild ^a   Ehninger, Gerhard ^c   Schmidt, Christian A ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Drug resistance; Protein binding; Relapse

Indexed keywords

ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; C REACTIVE PROTEIN; IMATINIB; MESSENGER RNA; OROSOMUCOID; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG PROTEIN BINDING; ENZYME INHIBITION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MALE; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE; BLOOD; CASE CONTROL STUDY; CELL CULTURE; GENETICS; METABOLISM; MIDDLE AGED; MYELOID LEUKEMIA; PATHOLOGY; TIME;

AGED; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; OROSOMUCOID; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RNA, MESSENGER; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 18344396578     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.2002.0493     Document Type: Article

References (25)

1. Drug binding to human alpha-1-acid glycoprotein in health and disease
2. Evaluation of a radioimmunoassay for α1-acid glycoprotein to monitor therapy of cancer patients
3. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by 2 phenylaminopyrimidine derivative
4. Effects of a selective inhibitor of the Abl tyrosinekinase on the growth of Bcr-Abl positive cells
5. + leukemic cells and induces apoptosis
6. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells
7. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
8. A phase II study of STI571 in adult patients with Philadelphia chromosome positive leukemia in accelerated phase
9. Phase II study of STI571, a tyrosine kinase inhibitor, in patients (pts) with resistant or refractory Philadelphia chromosome-positive chronic myeloid leukemia (Ph+-CML)
10. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia
11. Activity of a specific inhibitor of the bcr-abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
12. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
13. Roots of clinical resistance to STI-571 cancer therapy
14. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells trough gene amplification
15. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
16. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
17. Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571
18. Vorläufige referenzbereiche für 14 proteine im serum (für Erwachsene) nach standardisierung immunchemische methoden unter bezug auf das internationale referenzmaterial CRM 470
19. A new international reference preparation for proteins in human serum
20. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
21. Applicability of an absolute quantitative procedure to monitor intra-individual bcr/abl transcript kinetics in clinical samples of chronic myelogenous leukemia patients
22. A highly sensitive and specific fluorescence RT-PCR assay for the pseudogene free detection of β-actin transcripts as quantitative reference
23. α1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571
24. Elevated levels of the plasma protein alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis mediate pharmacological resistance to Gleevec (STI571, Imatinib) in vitro
25. Leucocyte surface origin of human α-1 acid glycoprotein (orosomucoid)